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and mid-2005 were retrieved from MEDLINE, conference pro-
ceedings, and governmental databases using search terms
“prostate cancer”, “prostatic neoplasm”, or similar, combined
with a comprehensive list of cost-related search terms. Articles
that provided economic data at an individual or societal level
were retrieved in full text and analyzed by study type, design,
endpoints, results, and other characteristics. RESULTS: Of 1169
abstracts retrieved, 186 met the inclusion criteria, of which most
(133 articles, 71.5%) were published since 1999. More than half
of the economic evaluations were retrospective, based on chart
reviews and database analyses (101, 54.3%). Others were
prospective evaluations based on clinical trials or observational
studies (73, 39.2%), and economic modeling of PCA screening
strategies (12, 6.5%). Cost-of-illness studies were completed in
eight developed countries. Assessments of cost per treatment
and/or per cancer stage (16, 8.6%) and cost per patient (11,
5.9%) were conducted primarily in the U.S., as were cost studies
of mass screening (25, 13.4%) and diagnostic modalities (15,
8.1%). Cost evaluations of curative treatments (43, 23.1%)
focused primarily on androgen suppression therapy (13, 7.0%),
as well as radical prostatectomy (10, 5.4%), radiation therapy
(10, 5.4%), or combination therapies (10, 5.4%). Cost assess-
ments of palliative care (21, 11.3%) focused on hormonal
therapy (16, 8.6%). Studies of indirect costs, costs of pharma-
ceutical preventions (e.g. ﬁnasteride) and the economic impact
of recurrence after treatment failure were scarce or unavailable.
CONCLUSIONS: As the population ages and as earlier detec-
tion become more common, PCA is becoming a more important
focus of economic assessment. Cost comparisons among treat-
ments or diagnostic modalities will remain challenging without
standardized assessments of clinical outcomes that make evalu-
ation of treatment effectiveness comparable across regimens.
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A METHOD TO REMOVE CONTINUOUS ENROLLMENT
REQUIREMENT FROM PHARMAECONOMIC STUDIES
Baser O
Thomson-Medstat, Ann Arbor, MI, USA
OBJECTIVE: Continuous enrolment requirement becoming a
“rule” rather than “exception” in pharmaeconomical studies.
However, continuous enrolment requirement contains potential
bias especially patients with incomplete data structurally differ-
ent from the ones with complete data. Moreover, for studies
involving rare diseases the requirement signiﬁcantly reduces
sample size and creates power issues. In this paper, we outline
the methodology which can be used to remove continuous
requirement. METHODS: This is a two stage method. First, we
estimate probability of being continuously enrolled using every
observation in our data set. This estimation can be done either
with parametric methods (such as logit, probit) or non-
parametric methods (such as Kaplan-Meier). Then according to
these probabilities we create a weight which is inverse of the esti-
mated probabilities at ﬁrst stage. Using these weights and only
observations which are continuously enrolled we estimate
weighted least square models at the second stage. Therefore
second stage regressions use probabilities containing information
from everybody at the ﬁrst stage. We showed that this eliminate
possible selection bias due to continuous enrolment. RESULTS:
We used medicare claim ﬁles for application. A total of 773
patients with incident cases of lung, prostate, colon and breast
cancer were analyzed for two years of cost. Continuous enrol-
ment requirement would decrease the sample size to 541 and
would create potential selection bias. We estimated the results
with and without continuous enrolment requirement and
showed that the results are statistically different from each other
(p = 0.000). CONCLUSIONS: Continuous enrolment require-
ment should not be applied blindly. Data sets created based on
this requirement yields consistent results if there is no systematic
differences between complete and incomplete observations.
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MODELING AND ESTIMATING PREFERENCES OVER
TREATMENTS FOR BREAST CANCER:APPLIED 
CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND
UNITED STATES
Walzer S1, Memran M2, Morlotti L1
1Analytica International, Loerrach, Germany, 2Analytica International,
New York, NY, USA
OBJECTIVES: The relative importance of product attributes for
the treatment of breast cancer were derived by applying conjoint
analyses in the US and Europe. The possible differences of the
prescribing behavior between physicians in Europe and the US
were analyzed. METHODS: Hypothetical attributes for phar-
maceutical products to treat breast cancer in various disease
phases were developed. Besides efﬁcacy and side effects the costs
for the products were also included as an attribute. Orthogonal
scenarios were derived and implemented in the questionnaire.
Questions about physician’s background, prescribing behaviors
and socioeconomic parameters were also developed and pre-
tested. The ﬁnal survey was done in the US and ﬁve different
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European countries (France, Germany, Italy, UK). Additionally
it was tested which inﬂuence a generic product would have on
the relative importance of product attributes. RESULTS: The
conjoint analyses resulted in the fact that there were major dif-
ferences between the relative importance of attributes between
physicians in Europe and the US. In the US efﬁcacy was the most
preferable attribute. Even when a generic drug would enter the
market efﬁcacy would still be the most important attribute—on
a lower level than for the “branded” product market but still the
most important. In Europe the most important attribute was 
the cost. Even when a generic product would enter the market
the costs would be the most important factor. CONCLUSIONS:
The discussions about the increasing health care costs across
Europe could have a major impact on the potential prescribing
behavior of physicians. Even in the breast cancer market which
is highly under public view the pressure on health care budget is
changing the relative importance of products. In the US where
these discussions are not as intensive as in Europe this conclu-
sion cannot be found.
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MAPPING FACT-P AND EORTC QLQ-C30 TO THE EQ-5D
HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY
PROSTATE CANCER PATIENTS
Wu E1, Mulani P2, Farrell MH1, Sleep D2
1Analysis Group, Inc, Boston, MA, USA, 2Abbott Laboratories, Abbott
Park, IL, USA
OBJECTIVES: To construct and validate a prediction model of
health utility (EQ-5D) for metastatic hormone-refractory prostate
cancer (HRPCA) patients using cancer-speciﬁc health-related
quality of life (HRQL) measures. METHODS: Data were
obtained from a multicenter, multinational observational study
of metastatic HRPCA patients conducted during 2002–2004. In
addition to clinical and resource utilization, health utility (EQ-
5D) and HRQL (Functional Assessment of Cancer Therapy—
Prostate [FACT-P] and European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire [EORTC
QLQ-C30]) data were collected. Predictive validity of ordinary
least square (OLS), Tobit, and median regressions of various
model speciﬁcations were tested using cross-validation samples.
The selected speciﬁcation was then further reﬁned and tested for
alternative model speciﬁcations and restrictions. RESULTS: OLS
regression with both HRQL measures as individual components
and patient demographics was the best performing model. It
explained 58.2% of the observed EQ-5D variation in the valida-
tion sample. A model including only the prostate cancer–speciﬁc
HRQL measure, FACT-P, explained 53.5% of the observed EQ-
5D variation. Both models have good ability to distinguish
patients with high health utility from those with low utility for
cutoff points between the 20th and 80th percentiles of observed
EQ-5D values. CONCLUSIONS: The prediction models devel-
oped have good predictive validity. These algorithms enable
researchers to translate cancer–speciﬁc HRQL measures to health
utility in metastatic HRPCA patients. The ﬁndings will help
perform utility adjustments in cost-utility analyses.
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VALIDATION OF AN INTERNET-BASED PATIENT 
HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE:
DATA FROM CAPSURE
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1University of California, San Francisco, San Francisco, CA, USA,
2Secure Outcomes Corporation, Santa Clara, CA, USA, 3TAP
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OBJECTIVES: The purpose of this validation study was to test
the accuracy and acceptability of an Internet-based questionnaire
(Qx) assessing health-related quality of life (HRQoL) among
subjects in CaPSURE, a longitudinal study of health outcomes
among men with prostate cancer. METHODS: Active partici-
pants were sent a ﬂyer with their usual bi-annual Qx offering the
opportunity to test the new Internet version and were paid $25
for their participation. Volunteers were randomized to one of
two Qx administration groups (paper-then-Internet or Internet-
then-paper). The SF-36 and the UCLA Prostate Cancer Index
(PCI) comprised the HRQoL Qx. A 10-item survey designed to
measure patient preference of administration was administered
after completion of both modalities. Descriptive statistics,
Pearson correlation coefﬁcients, and percent agreement were
used to assess comparability between these two methods of
administration. RESULTS: A convenience sample of 245 subjects
volunteered to participate; 209 (85%) completed both paper and
online Qx. Subject median age was 63 years-old (range 46–83).
The majority of respondents were white (97%), college educated
(66%) and had an income of >$75,000/year (46%). With few
exceptions, correlation coefﬁcients for the HRQoL multi-level
items were high (0.66–0.97) and the percent agreement for
yes/no items was also very high (>0.89). Subjects rated both
methods of administration favorably, although the Internet was
rated as somewhat more convenient and faster to complete.
There were no differences between the two versions on respon-
dent ratings for ease of reading, ease of answer completion, con-
fusion or stress. 70% preferred the Internet mode; 21% had no
preference and 9% preferred paper. CONCLUSIONS: Adminis-
tration of the HRQoL Qx, including SF-36 and PCI domains,
demonstrated a high correlation between the Internet and the
paper-and-pencil methods. The Internet was a well-accepted
mode among this select group of older men with prostate cancer.
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DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC,
NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET),TO
MEASURE PATIENTS’ PERCEPTION OF THE EFFECTS OF
DISEASE ON THEIR QUALITY OF LIFE (QOL)
Vinik EJ, Ford-Molvik SL,Vinik AI
Eastern Virginia Medical School, Norfolk,VA, USA
OBJECTIVE: Develop/validate a quality of life questionnaire for
capturing the unique spectrum of symptoms and impact on phys-
ical/psychological functioning related to neuroendocrine tumors
and eliciting patients’ own perceptions of their illness, providing
a guide to therapeutic options. METHODS: A total of 103 sub-
jects from a Philadelphia Neuroendocrine Tumor (NET) Con-
ference completed the QOL-NET. Seventy-two subjects were
females (mean age 56.29 + 1.03 years); and 27 were males (mean
age 54.89 + 0.95 years). The population was predominately Cau-
casian (92.2%). On the data, we performed an exploratory
factor analysis using a forced 7-factor varimax rotation. A
descriptive statistical analysis was completed on the total QOL
score and seven factors. Internal consistency was estimated using
Cronbach’s alpha coefﬁcient. Test-retest reliability over a 4–6
week period was assessed by a pairwise t-test on data from a
subset of 20 subjects. RESULTS: All 72 questions loaded into
the 7 domains, which we called: Factor 1 = Depression; Factor
2 = Flushing; Factor 3 = Respiratory; Factor 4 = Gastrointesti-
nal; Factor 5 = Cardiovascular; Factor 6 = Physical Functioning;
Factor 7 = Positive Attitude. Seventy-two items on the forced
seven factor solution accounted for 71.74% of the variance. If
items loaded with a score ≥0.35 on more than one factor, the
highest loading was used. The summary statistics for the Total
QOL and each domain: Total QOL, 76.80 ± 4.80; Factor 1,
